Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1585

1.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA.

Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1.

2.

Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.

Abudagga A, Sun SX, Tan H, Solem CT.

Int J Chron Obstruct Pulmon Dis. 2013;8:175-85. doi: 10.2147/COPD.S40437. Epub 2013 Apr 9.

3.

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.

Moll K, Sun SX, Ellis JJ, Howe A, Amin A.

Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:565-76. doi: 10.2147/COPD.S79025. eCollection 2015.

4.

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Simoni-Wastila L, Blanchette CM, Qian J, Yang HW, Zhao L, Zuckerman IH, Pak GH, Silver H, Dalal AA.

Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.

PMID:
19948302
5.

Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.

AbuDagga A, Sun SX, Tan H, Solem CT.

J Med Econ. 2013;16(3):421-9. doi: 10.3111/13696998.2013.766614. Epub 2013 Jan 29.

PMID:
23336296
6.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

8.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.

Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

J Med Econ. 2011;14(3):315-23. doi: 10.3111/13696998.2011.576295. Epub 2011 Apr 18.

PMID:
21500975
9.

The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data.

Kim J, Rhee CK, Yoo KH, Kim YS, Lee SW, Park YB, Lee JH, Oh Y, Lee SD, Kim Y, Kim K, Yoon H.

Int J Chron Obstruct Pulmon Dis. 2013;8:561-8. doi: 10.2147/COPD.S48577. Epub 2013 Nov 19.

10.

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease.

Dalal AA, Roberts MH, Petersen HV, Blanchette CM, Mapel DW.

Int J Chron Obstruct Pulmon Dis. 2010 Dec 31;6:13-22. doi: 10.2147/COPD.S15455.

11.

Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009.

Dalal AA, Liu F, Riedel AA.

Int J Chron Obstruct Pulmon Dis. 2011;6:533-42. doi: 10.2147/COPD.S24591. Epub 2011 Oct 14.

12.

Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes.

Allen-Ramey FC, Gupta S, DiBonaventura MD.

Int J Chron Obstruct Pulmon Dis. 2012;7:779-87. doi: 10.2147/COPD.S35501. Epub 2012 Nov 22.

13.

[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].

Jahnz-Rózyk K, Targowski T, From S.

Pol Merkur Lekarski. 2009 Mar;26(153):208-14. Polish.

PMID:
19388534
14.

Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients.

Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW.

Int J Chron Obstruct Pulmon Dis. 2012;7:1-9. doi: 10.2147/COPD.S27032. Epub 2012 Jan 18.

15.

Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.

Chiang CH.

Respirology. 2008 Sep;13(5):689-94. doi: 10.1111/j.1440-1843.2008.01308.x. Epub 2008 May 29.

PMID:
18513247
16.

Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.

Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 23;12:735-744. doi: 10.2147/COPD.S112256. eCollection 2017.

17.

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.

Menzin J, Boulanger L, Marton J, Guadagno L, Dastani H, Dirani R, Phillips A, Shah H.

Respir Med. 2008 Sep;102(9):1248-56. doi: 10.1016/j.rmed.2008.04.009. Epub 2008 Jul 11.

18.

Economic burden of chronic bronchitis in the United States: a retrospective case-control study.

Blanchette CM, Roberts MH, Petersen H, Dalal AA, Mapel DW.

Int J Chron Obstruct Pulmon Dis. 2011 Jan 13;6:73-81. doi: 10.2147/COPD.S15882.

19.

COPD exacerbation frequency and its association with health care resource utilization and costs.

Dhamane AD, Moretz C, Zhou Y, Burslem K, Saverno K, Jain G, Renda A, Kaila S.

Int J Chron Obstruct Pulmon Dis. 2015 Dec 3;10:2609-18. doi: 10.2147/COPD.S90148. eCollection 2015.

20.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.

Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

COPD. 2010 Jun;7(3):214-28. doi: 10.3109/15412555.2010.481697. Review.

PMID:
20486821

Supplemental Content

Support Center